Moleculin Biotech, Inc. Stock-Based Compensation
Moleculin Biotech, Inc. (MBRX) reported Stock-Based Compensation of $816.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $436.00K, a 4.56% increase year-over-year.
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $380.00K, a 21.65% decline year-over-year.
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $459.00K, a 7.49% increase year-over-year.
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $303.00K, a 14.16% decline year-over-year.
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.66M, a 3.59% decline from fiscal 2024.
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.73M, a 13.00% decline from fiscal 2023.
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.98M, a 12.79% decline from fiscal 2022.
- Moleculin Biotech, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $2.27M, a 4.13% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 2 month | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 5 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $436.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $816.00K 10-Q · filed 2026-08-13 | $1.27M derived: sum of 3 quarters · filed 2026-08-13 | $1.58M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2026-03-31 | $380.00K 10-Q · filed 2026-05-14 | $839.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.14M derived: sum of 3 quarters · filed 2026-05-14 | $1.56M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-12-31 | $459.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $762.00K derived: sum of 2 quarters · filed 2026-03-18 | $1.18M derived: sum of 3 quarters · filed 2026-08-13 | $1.66M 10-K · filed 2026-03-18 | ||||||
| 2025-09-30 | $303.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $720.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.21M 10-Q · filed 2025-11-13 | $1.63M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-06-30 | $417.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $902.00K 10-Q · filed 2026-08-13 | $1.33M derived: sum of 3 quarters · filed 2026-08-13 | $1.68M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-03-31 | $485.00K 10-Q · filed 2026-05-14 | $912.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.26M derived: sum of 3 quarters · filed 2026-05-14 | $1.72M derived: sum of 4 quarters · filed 2026-05-14 | ||||||
| 2024-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $780.00K derived: sum of 2 quarters · filed 2026-03-18 | $1.23M derived: sum of 3 quarters · filed 2026-03-18 | $1.73M 10-K · filed 2026-03-18 | ||||||
| 2024-09-30 | $353.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $806.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.30M 10-Q · filed 2025-11-13 | $1.78M derived: sum of 4 quarters · filed 2025-11-13 | ||||||
| 2024-06-30 | $453.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $946.00K 10-Q · filed 2025-08-12 | $1.43M derived: sum of 3 quarters · filed 2025-08-12 | $1.92M derived: sum of 4 quarters · filed 2025-08-12 | ||||||
| 2024-03-31 | $493.00K 10-Q · filed 2025-05-13 | $972.00K derived: sum of 2 quarters · filed 2025-05-13 | $1.47M derived: sum of 3 quarters · filed 2025-05-13 | $1.98M derived: sum of 4 quarters · filed 2025-05-13 | ||||||
| 2023-12-31 | $479.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $972.00K derived: sum of 2 quarters · filed 2025-03-21 | $1.49M derived: sum of 3 quarters · filed 2025-03-21 | $1.98M 10-K · filed 2025-03-21 | ||||||
| 2023-09-30 | $493.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $1.01M derived: sum of 2 quarters · filed 2024-11-08 | $1.50M 10-Q · filed 2024-11-08 | $2.04M derived: sum of 4 quarters · filed 2024-11-08 | ||||||
| 2023-06-30 | $513.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.01M 10-Q · filed 2024-08-13 | $1.55M derived: sum of 3 quarters · filed 2024-08-13 | $2.25M derived: sum of 4 quarters · filed 2024-08-13 | ||||||
| 2023-03-31 | $499.00K 10-Q · filed 2024-05-10 | $1.03M derived: sum of 2 quarters · filed 2024-05-10 | $1.73M derived: sum of 3 quarters · filed 2024-05-10 | $2.25M derived: sum of 4 quarters · filed 2024-05-10 | ||||||
| 2022-12-31 | $535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $1.23M derived: sum of 2 quarters · filed 2024-03-22 | $1.75M derived: sum of 3 quarters · filed 2024-03-22 | $2.27M 10-K · filed 2024-03-22 | ||||||
| 2022-09-30 | $699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.21M derived: sum of 2 quarters · filed 2023-11-13 | $1.74M 10-Q · filed 2023-11-13 | $2.30M derived: sum of 4 quarters · filed 2023-11-13 | ||||||
| 2022-06-30 | $514.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.04M 10-Q · filed 2023-08-10 | $1.60M derived: sum of 3 quarters · filed 2023-08-10 | $2.58M derived: sum of 4 quarters · filed 2023-08-10 | ||||||
| 2022-03-31 | $527.00K 10-Q · filed 2023-05-10 | $1.08M derived: sum of 2 quarters · filed 2023-05-10 | $2.06M derived: sum of 3 quarters · filed 2023-05-10 | $2.50M derived: sum of 4 quarters · filed 2023-05-10 | ||||||
| 2021-12-31 | $556.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $1.53M derived: sum of 2 quarters · filed 2023-03-22 | $1.97M derived: sum of 3 quarters · filed 2023-03-22 | $2.37M 10-K · filed 2023-03-22 | ||||||
| 2021-09-30 | $979.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.41M derived: sum of 2 quarters · filed 2022-11-10 | $1.82M 10-Q · filed 2022-11-10 | $2.23M derived: sum of 4 quarters · filed 2022-11-10 | ||||||
| 2021-06-30 | $433.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $838.00K 10-Q · filed 2022-08-12 | $1.25M derived: sum of 3 quarters · filed 2022-08-12 | $1.71M derived: sum of 4 quarters · filed 2022-08-12 | ||||||
| 2021-03-31 | $405.00K 10-Q · filed 2022-05-11 | $820.00K derived: sum of 2 quarters · filed 2022-05-11 | $1.28M derived: sum of 3 quarters · filed 2022-05-11 | $1.69M derived: sum of 4 quarters · filed 2022-05-11 | ||||||
| 2020-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $875.00K derived: sum of 2 quarters · filed 2022-03-24 | $1.28M derived: sum of 3 quarters · filed 2022-03-24 | $1.68M 10-K · filed 2022-03-24 | ||||||
| 2020-09-30 | $460.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $868.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.26M 10-Q · filed 2021-11-10 | $1.65M derived: sum of 4 quarters · filed 2021-11-10 | ||||||
| 2020-06-30 | $408.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $805.00K 10-Q · filed 2021-08-11 | $1.19M derived: sum of 3 quarters · filed 2021-08-11 | $1.68M derived: sum of 4 quarters · filed 2021-08-11 | ||||||
| 2020-03-31 | $397.00K 10-Q · filed 2021-05-12 | $779.00K derived: sum of 2 quarters · filed 2021-05-12 | $1.27M derived: sum of 3 quarters · filed 2021-05-12 | $1.59M derived: sum of 4 quarters · filed 2021-05-12 | ||||||
| 2019-12-31 | $382.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $871.00K derived: sum of 2 quarters · filed 2021-03-24 | $1.19M derived: sum of 3 quarters · filed 2021-03-24 | $1.54M 10-K · filed 2021-03-24 | ||||||
| 2019-09-30 | $489.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $807.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.16M 10-Q · filed 2020-11-12 | $1.47M derived: sum of 4 quarters · filed 2020-11-12 | ||||||
| 2019-06-30 | $318.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $666.00K 10-Q · filed 2020-08-12 | $981.00K derived: sum of 3 quarters · filed 2020-08-12 | $1.23M derived: sum of 4 quarters · filed 2020-08-12 | ||||||
| 2019-03-31 | $348.00K 10-Q · filed 2020-05-11 | $663.00K derived: sum of 2 quarters · filed 2020-05-11 | $907.00K derived: sum of 3 quarters · filed 2020-05-11 | $1.25M derived: sum of 4 quarters · filed 2020-05-11 | ||||||
| 2018-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $559.00K derived: sum of 2 quarters · filed 2020-03-19 | $898.00K derived: sum of 3 quarters · filed 2020-03-19 | $1.14M 10-K · filed 2020-03-19 | ||||||
| 2018-09-30 | $244.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $583.00K derived: sum of 2 quarters · filed 2019-11-12 | $825.00K 10-Q · filed 2019-11-12 | $1.04M derived: sum of 4 quarters · filed 2019-11-12 | ||||||
| 2018-06-30 | $339.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-16 | $581.00K 10-Q · filed 2019-08-16 | $801.00K derived: sum of 3 quarters · filed 2019-08-16 | $1.07M derived: sum of 4 quarters · filed 2019-08-16 | ||||||
| 2018-03-31 | $242.00K 10-Q · filed 2019-05-13 | $462.00K derived: sum of 2 quarters · filed 2019-05-13 | $730.00K derived: sum of 3 quarters · filed 2019-05-13 | $839.00K derived: sum of 4 quarters · filed 2019-05-13 | ||||||
| 2017-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $488.00K derived: sum of 2 quarters · filed 2019-02-21 | $597.00K derived: sum of 3 quarters · filed 2019-02-21 | $707.00K 10-K · filed 2019-02-21 | ||||||
| 2017-09-30 | $268.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $377.00K derived: sum of 2 quarters · filed 2018-11-13 | $487.00K 10-Q · filed 2018-11-13 | $602.00K derived: sum of 4 quarters · filed 2018-11-13 | ||||||
| 2017-06-30 | $109.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-10 | $219.00K 10-Q · filed 2018-08-10 | $334.00K derived: sum of 3 quarters · filed 2018-08-10 | $381.00K derived: sum of 4 quarters · filed 2018-08-10 | ||||||
| 2017-03-31 | $110.00K 10-Q · filed 2018-05-14 | $225.00K derived: sum of 2 quarters · filed 2018-05-14 | $272.00K derived: sum of 3 quarters · filed 2018-05-14 | $432.00K derived: sum of 4 quarters · filed 2018-05-14 | ||||||
| 2016-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-28 | $162.00K derived: sum of 2 quarters · filed 2018-03-28 | $322.00K derived: sum of 3 quarters · filed 2018-03-28 | $324.00K 10-K · filed 2018-03-28 | $323.97K 10-K · filed 2017-04-03 | |||||
| 2016-09-30 | $47.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $207.00K derived: sum of 2 quarters · filed 2017-11-13 | $209.00K 10-Q · filed 2017-11-13 | $208.94K 10-Q · filed 2016-11-21 | ||||||
| 2016-06-30 | $160.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $162.00K 10-Q · filed 2017-08-11 | $161.50K 10-Q · filed 2016-08-15 | |||||||
| 2016-03-31 | $2.00K 10-Q · filed 2017-05-12 | $2.10K 10-Q · filed 2016-06-16 | ||||||||
| 2015-12-31 | $0.00 10-K · filed 2017-04-03 | |||||||||
| 2015-09-30 | $0.00 10-Q · filed 2016-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |